Get in touch with NEXO Beauty Labs Company
Cosmetic Factory Capabilities
Cosmetic Factory Capabilities for Beauty Brands
NEXO Beauty Labs’ cosmetic factory capabilities connect product concepts to commercial production across skincare, hair care, and body care. We combine professional research and development capabilities, formulation innovation, and scalable manufacturing. We combine global market insights with product development and manufacturing support.
- Manufacturing foundation since 1999
- OEM and ODM routes
- Global project support
Share the formula status, product format, packaging direction, target market, and expected quantity for a project-specific review.
1999
OEM & ODM
Global
Factory Capability at a Glance
A capability page is the start of due diligence
Factory Capability Summary for Product Teams
Product development
Formulation support
Manufacturing coordination
Formula and Packaging Decisions Stay Connected
The risk is a formula-package mismatch because a laboratory formula does not automatically scale into a repeatable manufacturing process. Process development needs the formula strategy, manufacturing sequence, packaging interaction, expected variability, and control points to travel together.
Formula-side inputs
- Target product profile and intended use
- Existing formula, benchmark, or open formulation brief
- Raw material constraints and ingredient preferences
- Texture, appearance, viscosity, fragrance, and claims direction
Package-side inputs
- Tube, bottle, jar, sachet, or other primary package
- Fill volume and closure direction
- Artwork, label, secondary packaging, and market language
- Compatibility questions that must be resolved before scaling
Regulatory category follows intended use
In the United States, the Food and Drug Administration (FDA) explains that intended use and product claims help determine whether a product is a cosmetic, a drug, both, or soap. A category label is not a substitute for an intended-use review, and a common assumption about “cosmetic” status can therefore be wrong.
Factory Capability Evidence Map
This table separates confirmed NEXO facts from project variables that still require review. It gives a brand team a usable starting point without borrowing a competitor’s numbers. The FDA inspection checklist supplies external context for facility and quality questions, not proof of NEXO certification.
| Capability fact | Confirmed value | How to use it |
|---|---|---|
| Manufacturing foundation | Since 1999 | Establishes the history stated by NEXO. |
| Cosmetic manufacturing expertise | More than 25 years | Frames experience without adding facility or capacity figures. |
| International business team | Since 2020 | Supports the global project-contact context. |
| Core product categories | 3 | Skincare, hair care, and body care. |
| Development routes | 2 | OEM and ODM. |
| Capability-match brief | 7 inputs | Category, market, formula, format, packaging, quantity, launch window. |
| Bound visual library | 24 client-supplied factory images | Provides visual context without proving certification or capacity. |
Quality Evidence for Market-Ready Cosmetics
Quality control is not one certificate, one inspection photo, or one final product check. A certificate can create false confidence if buyers do not request product-specific safety, stability, challenge and compatibility evidence. The risk persists because facility and product documents answer different questions; NEXO Beauty Labs uses the FDA checklist as external buyer context.
Facility-level evidence
Ask for the issuer, date, site scope, activity scope, and current status of any facility document. Do not treat a facility certificate as product-specific safety evidence.
Product-level evidence
Match safety substantiation, stability testing, compatibility work, and claims support to the exact formula, package, intended use, and target market.
Project-level responsibility
Define the specification, approval path, deviation route, change control, release documents, and record access in the commercial agreement.
Evidence must match the decision
The risk of mismatched evidence persists because facility and product documents answer different questions. Contrary to a common assumption, a facility certificate is not a substitute for formula-, package-, claim-, and market-specific evidence. NEXO Beauty Labs uses the FDA checklist as external buyer context.
How We Work: A Coordinated Cosmetic Manufacturing Workflow
Brief alignment
Development route
Sample review
Scale-up review
Commercial handoff
Cosmetic Factory Capability Assessment Tools
Factory Capability Match
Check whether your current project brief contains the seven inputs needed for a useful factory review. This tool measures brief completeness; it does not approve a formula, quote a project, or confirm manufacturing fit.
Cosmetic Project Brief Builder
Turn a loose product idea into a copyable project brief. The output records what the brand knows and clearly marks open items; it does not create a quote or supply missing commercial terms.
Responsibility Evidence Map
Mark whether each project responsibility is open, has an owner, or has both an owner and named evidence. The score measures mapping completeness only; it does not judge compliance or replace an agreement.
FAQ: Frequently Asked Questions
Yes. NEXO supports both routes.
Provide the product category, target market, formula status, product format, packaging direction, expected quantity, and target launch window. Those seven inputs make the next conversation specific.
No. It requires a scale-up review first.
No. Facility-level documents and product-specific safety evidence answer different questions, so review issuer, date, site scope, product scope, and market responsibility separately.
They depend on the formula, package, quantity, development route, target market, and documentation needs. NEXO evaluates those terms after reviewing the project brief.
Our international team supports global beauty brands, e-commerce companies, distributors, and private label partners. Project fit is confirmed through a capability review rather than a generic brand label.
Formula ownership is not automatic in contract manufacturing. Before development starts, the agreement should define background intellectual property, new project work, permitted use, transfer rights, exclusivity, confidentiality, and termination consequences. If ownership changes after a payment or milestone, that trigger should be written explicitly.
Review the legal contracting party, proposed production site, process ownership, subcontracting boundaries, quality responsibilities, document pack, and change-control route. Confirm which statements apply to the exact formula, package, market, and facility in your project. Factory photos provide useful context, but they do not replace those checks.




